Docetaxel and Cetuximab in Treating Patients With Metastatic Prostate Cancer
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing.
Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some
block the ability of tumor cells to grow and spread. Others find tumor cells and help kill
them or carry tumor-killing substances to them. Cetuximab may also stop the growth of
prostate cancer by blocking blood flow to the tumor. Giving docetaxel together with cetuximab
may kill more tumor cells.
PURPOSE: This phase II trial is studying the side effects of giving docetaxel together with
cetuximab and to see how well it works in treating patients with metastatic prostate cancer.